AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30236025
Drug: α-1 antitrypsin
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-1 antitrypsin (AAT) therapy, administered as multiple repeated infusions (up to 36) over a long-term period (up to 5 years)
Trial: 30236252
Drug: Intraoperative ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative ventilation with high tidal volume (8.8 ml/kg) and low PEEP, without recruitment manoeuvres.
Trial: 30239252
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulfate liposome injection (VSLI) 2.25 mg/m²
Trial: 30239559
Drug: Psyllium fiber
RxNorm normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium fiber (median dose of ∼10.2 g)
Trial: 30240327
Drug: Lurbinectedin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm A (BRCA1/2 mutated)
Trial: 30240327
Drug: Lurbinectedin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm B (unselected)
Trial: 30240327
Drug: Lurbinectedin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in patients with BRCA2 mutations
Trial: 30240471
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 1200 mg daily for 6 months
Trial: 30240852
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg, orally once daily)
Trial: 30240852
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care EGFR TKI (gefitinib 250 mg or erlotinib 150 mg, orally once daily)
Trial: 30240937
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily for 16 weeks
Trial: 30240937
Drug: Galcanezumab 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 5, 50, 120, and 300 mg subcutaneously every 4 weeks, twice
Trial: 30241271
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine equivalents prescribed (30 mg median daily dose for morphine and tramadol).
Trial: 30241562
Drug: Xue-Fu-Zhu-Yu Capsule
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xue-Fu-Zhu-Yu Capsule (XFZYC)
Trial: 30242747
Drug: Sedation according
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation according to an algorithm promoting alternatives to continuous infusion of midazolam or propofol (intervention group)
Trial: 30243299
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 patients without treatment)
Trial: 30243418
Drug: Buprenorphine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (various formulations: oral, injection, implant)
Trial: 30243418
Drug: Daily buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buprenorphine formulations (tablet or film)
Trial: 30243418
Drug: Weekly or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly or monthly injection
Trial: 30243418
Drug: Bi-annual implant
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-annual implant
Trial: 30243418
Drug: Past buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past buprenorphine prescription
Trial: 30243800
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with Tremelimumab
Trial: 30244613
Drug: Brexpiprazole as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole as adjunctive treatment
Trial: 30245163
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) of nucleus accumbens (NAc) and anterior limb of the internal capsule (ALIC)
Trial: 30249277
Drug: Vismodegib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (150 mg/day orally) and Ruxolitinib (15 or 20 mg orally twice daily)
Trial: 30250733
Drug: Endotoxin core
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Endotoxin core antibody levels (EndoCAb)
Trial: 30250733
Drug: Staphylococcal antibody
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staphylococcal antibody levels
Trial: 30250733
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to varicella
Trial: 30251145
Drug: T cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell receptor excision circle (TREC) assay
Trial: 30252856
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin at a dose of 200 micrograms per kilogram administered on day 1 and day 8
Trial: 30253804
Drug: AMG 228
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 228 (1200 mg, administered intravenously every 3 weeks)
Trial: 30253804
Drug: AMG 228
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 228 (180-1200 mg, administered intravenously every 3 weeks)
Trial: 30253804
Drug: AMG 228
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 228 (doses > 360 mg, administered intravenously every 3 weeks)
Trial: 30253804
Drug: AMG 228
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 228 (monotherapy)
Trial: 30254130
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg/d
Trial: 30254130
Drug: Ibrutinib 280
RxNorm normalized name: ibrutinib 280 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 280 mg/d
Trial: 30254130
Drug: Ibrutinib 140
RxNorm normalized name: ibrutinib 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 140 mg/d
Trial: 30254130
Drug: Ibrutinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (all doses)
Trial: 30255476
Drug: Torasemide monotherapy
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide monotherapy (control group, n=20)
Trial: 30256541
Drug: Gedatolisib (89
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gedatolisib (89 mg, intravenous infusion)
Trial: 30256893
Drug: Lipid-rich test
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-rich test meal containing 20 mg [13C-10]-β-carotene
Trial: 30256905
Drug: Recombinant Zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Zoster Vaccine (RZV)
Trial: 30257076
Drug: Lean-body-weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean-body-weight-based dosing of pantoprazole (1.2 mg/kg)
Trial: 30258442
Drug: Low-Dose Mycophenolate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Mycophenolate Mofetil
Trial: 30258648
Drug: Thiamine 500
RxNorm normalized name: thiamine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 500 mg oral capsule once daily for 3 months
Trial: 30258648
Drug: Thiamine 500
RxNorm normalized name: thiamine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine 500 mg oral capsule once daily
Trial: 30260396
Drug: Insulin-modified frequently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-modified frequently sampled intravenous glucose test (IM-FSIGT)
Trial: 30260412
Drug: Fidaxomicin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin, 200 mg twice daily for 10 days
Trial: 30260415
Drug: Propofol infusions
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusions (10 sessions, dosed to suppress EEG activity for 15 minutes)
Trial: 30260415
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (20 patients)
Trial: 30261236
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (within PCI)
Trial: 30262659
Drug: Pomalidomide (POM)
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide (POM) 5 mg daily for 21 days every 28 days and Dexamethasone (DEX) 40 mg orally every week
Trial: 30263228
Drug: Schizophrenia Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schizophrenia Oral Health Profile (SOHP) questionnaire
Trial: 30264504
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy for advanced or metastatic NSCLC
Trial: 30264864
Drug: Eliglustat tartrate
RxNorm normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat tartrate 50 or 100 mg twice daily for 8 years
Trial: 30267561
Drug: Radiation Therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy Oncology Group (RTOG) contouring guidelines
Trial: 30268101
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line TB therapy
Trial: 30268483
Drug: lumretuzumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumretuzumab (monoclonal anti-HER3 antibody) in combination with erlotinib
Trial: 30269073
Drug: Nurse-led monitoring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led monitoring using the structured adverse drug reaction (ADRe) profile
Trial: 30270406
Drug: Meropenem-vaborbactam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days)
Trial: 30271191
Drug: Duloxetine (40-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (40-60 mg/day)
Trial: 30271191
Drug: Pregabalin (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300-600 mg/day)
Trial: 30274768
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure therapy (CPAP) used by 96% of patients with 68% total adherence.
Trial: 30274980
Drug: Matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched treatment based on genomic profile
Trial: 30275092
Drug: Intravenous Plazomicin
RxNorm normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Plazomicin
Trial: 30277031
Drug: Counselor-initiated or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselor-initiated or self-paced intervention promoting daily self-weighing
Trial: 30277089
Drug: Lenalidomide (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (target 25mg daily) plus dexamethasone for 18 cycles
Trial: 30277094
Drug: Plecanatide, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plecanatide, dosage and duration not specified
Trial: 30278378
Drug: Afatinib 30
RxNorm normalized name: afatinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 30 mg/day plus cetuximab 250 mg/m2
Trial: 30280586
Drug: ChonDux hydrogel
RxNorm normalized name: Chondrus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChonDux hydrogel scaffold implantation in combination with microfracture
Trial: 30280905
Drug: AD+HIV (treatment-naive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD+HIV (treatment-naive HIV diagnosis)
Trial: 30280906
Drug: Baseline 25-hydroxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline 25-hydroxy vitamin D <20 ng/mL
Trial: 30281207
Drug: Post-acute physical
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-acute physical therapy interventions
Trial: 30282468
Drug: Home Blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Blood Pressure Monitoring (HBPM) users; racial comparison of treatment intensification.
Trial: 30282468
Drug: Home Blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Blood Pressure Monitoring (HBPM) users; gender comparison of treatment intensification.
Trial: 30282673
Drug: ROTEM (EXTEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROTEM (EXTEM ML)
Trial: 30282677
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine (ADASUVE) 10 mg self-administered
Trial: 30282826
Drug: Aldesleukin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldesleukin (recombinant human IL-2) at a dose of 0.26 × 106 IU/m2 every 3 days
Trial: 30283914
Drug: Daily meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily meals preparation and service
Trial: 30284154
Drug: Everolimus (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (orally administered)
Trial: 30285518
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin (Teliso-V) 2.4 to 3.0 mg/kg
Trial: 30285741
Drug: Rectal pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal pressure measurement
Trial: 30285990
Drug: Unfiltered nanofat
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfiltered nanofat injections
Trial: 30286724
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen (FOLFOX: 5FU, leucovorin plus oxaliplatin)
Trial: 30286821
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonist (MRA) therapy
Trial: 30287268
Drug: Recruitment via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment via national registers, treatment centers, and social media
Trial: 30287613
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs
Trial: 30287613
Drug: Drug concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug concentrations of pyrazinamide, ethambutol, levofloxacin, moxifloxacin, cycloserine, prothionamide, para-aminosalicylate, and amikacin
Trial: 30287613
Drug: MIC determination
RxNorm normalized name: MIC
DrugBank: Methyl isocyanate (DB12765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC determination of pyrazinamide and other drugs
Trial: 30287673
Drug: Core treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core treatment for osteoarthritis in primary healthcare
Trial: 30288127
Drug: Video-call smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Trial: 30288127
Drug: Voice-call smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Trial: 30288327
Drug: Rifaximin-α 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin-α 550 mg
Trial: 30288700
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.5 mg) injections
Trial: 30289425
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (WP) supplementation (30 g, 2 times/d)
Trial: 30289425
Drug: Collagen peptides
RxNorm normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen peptides (CP) supplementation (30 g, 2 times/d)
Trial: 30289805
Drug: TriMix-100 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMix-100 g
Trial: 30289805
Drug: TriMix-300 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMix-300 g
Trial: 30289805
Drug: TriMix-300 g with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMix-300 g with HTI-300 g
Trial: 30289805
Drug: TriMix-300 g with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMix-300 g with HTI-600 g
Trial: 30289805
Drug: TriMix-300 g with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMix-300 g with HTI-900 g
Trial: 30291112
Drug: Eculizumab 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab 600 mg weekly for 4 weeks, then 900 mg every other week through week 26
Trial: 30291834
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine toothbrushing three times daily for 5 days before and after surgery
Trial: 30292651
Drug: MR haplotype
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR haplotype 1 (G-A haplotype)
Trial: 30294708
Drug: 4.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g/day multimatrix mesalamine tablets once daily for eight weeks (acute phase)
Trial: 30294708
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day multimatrix mesalamine for 12 months (maintenance phase)
Trial: 30295389
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment (n=75)
Trial: 30295389
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (n=28)
Trial: 30295816
Drug: Oral clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clomiphene citrate (50 mg) once daily for 30 days
Trial: 30296681
Drug: pNGVL4a-Sig/E7(detox)/HSP70 DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine followed by TA-HPV boost through skin scarification
Trial: 30297124
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (qHPV) administered at 0, 2, and 6 months
Trial: 30297385
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg orally every day plus bortezomib 1.3 mg/m² IV on days 1, 4, 8, and 11 of a 28-day cycle
Trial: 30297879
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEPO) treatment
Trial: 30298037
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for Insomnia Severity, details not available
Trial: 30298070
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of 20-30% iron-saturated bovine lactoferrin (bLf) twice a day
Trial: 30298070
Drug: 329.7 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 329.7 mg of ferrous sulfate once a day (control)
Trial: 30298340
Drug: Immunosignature analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosignature analysis using a 256-peptide signature derived from serum antibodies.
Trial: 30298340
Drug: Immunosignature analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosignature analysis using a 654-peptide signature derived from serum antibodies.
Trial: 30298381
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (RT) at a total dose of 20 Gy delivered BID in two consecutive days.
Trial: 30298444
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (1.5 pmol/kg/min dissolved in 500 ml of 0.9% saline)
Trial: 30298444
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 ml of 0.9% saline)